Evidence map›Paper›PMID 29560127›Full record

ArticleOncotarget2018

Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids.

Mans Broekgaarden, Imran Rizvi, Anne-Laure Bulin, Ljubica Petrovic, Ruth Goldschmidt, Iqbal Massodi, Jonathan P Celli, Tayyaba Hasan

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Necroptosis activation is associated with greater methylene blue-photodynamic therapy-induced cytotoxicity in human pancreatic ductal adenocarcinoma cells.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Supramolecular co-encapsulation of a photosensitizer and chemotherapeutic drug in cucurbit[8]uril for potential chemophototherapy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mans BroekgaardenWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Imran RizviWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Anne-Laure BulinWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Ljubica PetrovicDepartment of Physics, University of Massachusetts, Boston, MA 02125, USA.
Ruth GoldschmidtWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Iqbal MassodiWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Jonathan P CelliDepartment of Physics, University of Massachusetts, Boston, MA 02125, USA.
Tayyaba HasanWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
Harvard University · USMassachusetts General Hospital · USUniversity of Massachusetts Boston · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
Heterocellular 3D ovarian tumor arrays for imaging and mechanistic combinationsR01CA158415 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2012 to 2016
$2.0M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic PlatformsR00CA175292 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RIZVI, IMRAN · 2016 to 2019
$746k
Mechanism-based therapies for pancreatic cancer informed by stromal microrheologyR00CA155045 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CELLI, JONATHAN P · 2013 to 2015
$708k
Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic PlatformsK99CA175292 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI RIZVI, IMRAN · 2014 to 2015
$350k
Mechanism-based therapies for pancreatic cancer informed by stromal microrheologyK99CA155045 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CELLI, JONATHAN P · 2011 to 2012
$324k
NCI NIH HHS K99 CA155045NCI NIH HHS K99 CA175292NCI NIH HHS P01 CA084203NCI NIH HHS R00 CA155045NCI NIH HHS R00 CA175292NCI NIH HHS R01 CA158415NCI NIH HHS R01 CA160998
6 · The paper itself

Abstract

Effective treatment of advanced metastatic disease remains the primary challenge in the management of inoperable pancreatic cancer. Current therapies such as oxaliplatin (OxPt)-based chemotherapy regimens (FOLFIRINOX) provide modest short-term survival improvements, yet with significant toxicity. Photodynamic therapy (PDT), a light-activated cancer therapy, demonstrated clinical promise for pancreatic cancer treatment and enhances conventional chemotherapies with non-overlapping toxicities. This study investigates the capacity of neoadjuvant PDT using a clinically-approved photosensitizer, benzoporphyrin derivative (BPD, verteporfin), to enhance OxPt efficacy in metastatic pancreatic cancer. Treatment effects were evaluated in organotypic three-dimensional (3D) cultures, clinically representative models that bridge the gap between conventional cell cultures and

Indexed as

combination therapyexperimental medicineorganoid modelsphotochemotherapytranslational therapies

Identifiers

PMID29560127
PMCPMC5849191
OpenAlexW2789432349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.